The extracellular matrix secreted by cultured bovine smooth muscle cells (BSMC) contains an endothelial type plasminogen activator (PA) inhibitor. When PA is incubated with the matrix, a high molecular weight complex containing a truncated PA inhibitor is released into the supernatant. The inhibitor also dissociates from the matrix by treatment with glycine, pH 2.7, in its intact, functionally active, 45-kD form, whereas treatment of the matrix with thrombin results in the release of a cleaved, inactive, 41 kD PA inhibitor. Bowes melanoma cells but not smooth muscle cells cultured on BSMC matrices decrease available matrix associated PA inhibitor. PA inhibitor incorporated into the extracellular matrix may serve an important role in the regulation of plasminogen activator mediated matrix degradation.
Introduction
The serine proteases tissue plasminogen activator (t-PA)' (1) and urinary plasminogen activator (u-PA) (2) convert the zymogen plasminogen into the serine protease plasmin and thereby have been implied in various physiological and pathological processes including fibrinolysis (3) , cellular migration (4), neuronal outgrowth (5), ovulation (6) , activation of latent collagenase (7) , and tumor metastasis (8) . Whereas plasminogen activators (PAs) possess greatly restricted substrate specificity, plasmin cleaves a wide range of proteins. A complex regulatory system exists to ensure the localized and controlled generation of plasmin that involves the regulation of PA production and plasminogen activation. A variety of serine protease inhibitors limit t-PA, u-PA and plasmin activity (9) . Most cells synthesize both PA and their inhibitors and thereby determine the level of PA activity in the cellular microenvir- onment. This equilibrium is shifted toward an excess production of inhibitors by a number of cellular stimuli including thrombin (10) , endotoxin (1 1), lymphokines (12) (13) (14) , and glucocorticoids (15, 16) . Four distinct PA inhibitors, an endothelial PA inhibitor (PAI-1) (17) (18) (19) (20) , a placental PA inhibitor (PAI-2) (21), protease nexin (22) , and a recently described urinary inhibitor (23) possess different substrate specificities, kinetic properties, and tissue distribution. PAI-l and PAI-2 exhibit great specificity for t-PA and u-PA (24, 25) . Whereas PAI-l is acid stable and inactivates t-PA and u-PA with similar efficiency (26) , PAI-2 reacts more rapidly with u-PA and is acid sensitive (27) . Protease nexin (28) and the urinary inhibitor in the presence of heparin react rapidly with u-PA and thrombin but much slower with t-PA.
The extracellular matrix is composed ofa complex array of collagens, glycoproteins, and proteoglycans (29) . This tight network of adhesive proteins functions as a barrier to cellular migration. Activated nonmalignant cells as well as tumor cells secrete enzymes that degrade matrix constituents and facilitate cellular movement (30) . The extracellular matrix contains inhibitors of collagenases and stromolysin (31) that may play a role in preventing matrix destruction by invasive cells. In addition plasmin and u-PA affect matrix glycoproteins (32, 33) . We have recently shown that plasminogen binds to the surface of the extracellular matrix where its activation by t-PA is enhanced as compared with the fluid phase. In addition, the newly generated matrix-associated plasmin is protected from its fast acting inhibitor a2-plasmin inhibitor (34) . To effectively reduce plasmin-mediated matrix destruction, plasminogen activation rather than plasmin activity must be inhibited. We now present evidence that vascular extracellular matrix produced by cells in tissue culture contains a PA inhibitor. The localization and properties of this inhibitor suggest that it may play a regulatory role in the penetration of cells through the vessel wall. Methods Materials. [35SjMethionine and '25I-Na were purchased from New England Nuclear (Boston, MA), D-phenyl-d-alanyl-l-prolyl-l-arginine chloromethylketone (PPACK) from Calbiochem-Behring, La Jolla, CA, bovine serum albumin (BSA) from Miles Laboratories (Elkhart, M PPACK. To study the effects of cells on BSMC matrices, cells were trypsinized and the trypsin was inhibited with 10% fetal calf serum. After intensive washing in serum-free medium 3 X 105 cells per well were plated on the BSMC matrix. After a 4-h culture in serum-free medium, adherent cells were removed by a 5-min incubation with 25 mM NH40H, the matrices were washed three times with Tris-Tween buffer and extracted with acid for 1 h.
Production oflabeled matrices. BSMC were grown to confluency in 24 well plates. The cells were incubated for I h with methionine free minimal essential medium containing 2% fetal calf serum, 25 mM Hepes pH 7.2, 2 mM L-glutamine, penicillin, and streptomycin and labeled with 10 MCi [35S]methionine/ml for 8-12 h. Matrices were prepared as described and contained 6,000-8,000 cpm/well. Matrices were solubilized in sample buffer (0.625 M Tris/HCI, pH 6.8, 0.1% sodium dodecyl sulfate [SDS] , 25% glycerol, bromphenol blue, 100 mM dithiothreitol) and analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) and autoradiography.
Protein iodination. u-PA was labeled with '25I by the modified chloramine T method as previously described (37) Reverse zymography. Reverse zymography was carried out using the procedure for reverse fibrin autography ( 19) but casein was substituted for fibrinogen and thrombin. Briefly, SDS-PAGE gel pieces were first soaked in 2.5% Triton and H20 for 30 min each and then layed onto casein indicator gels (1.25% agarose, 2% Carnation dry milk; Carnation Co., Los Angeles, CA, 0.2 U/ml u-PA and 30 Mug/ml plasminogen). The gels were developed for 4.5 h at 37°C in a humidified chamber and stained with amido black.
Results
Complex formation between an extracellular matrix protein and plasminogen activators. Bovine smooth muscle cells synthesize an extracellular matrix that remains tightly adherent to the culture plate after removal of cells by treatment with 0.5% Triton X-100 and 25 mM NH40H. When such matrices were incubated with 1251 u-PA in Tris-Tween buffer, pH 7.4, a specific complex formed between u-PA and a matrix component that dissociated from the matrix and appeared in the supernatant ( Fig. 1 A) . Whereas reduced two-chain u-PA migrated with an apparent molecular weight of 30-35 kD ( Fig. 1 sized by BSMCs, PAs were incubated with biosynthetically labeled BSMC matrices and the supernatants analyzed by SDS-PAGE ( Fig. 1 B) . Supernatants from matrices incubated with Tris-Tween buffer contained a major band with an apparent molecular weight of 45 kD ( Fig. 1 Diisopropyl fluorophosphate inactivated plasminogen activators did not show any complex formation. Complex formation was accompanied by loss of u-PA enzymatic activity (Fig. 3) . u-PA (0.62 U) was incubated with matrices for increasing amounts of time and the u-PA-associated amidolytic activity in the supernatant was quantified fluorometrically at each timepoint. Maximal inhibition of u-PA occurred after 20 min while the amount of u-PA in the supernatant remained unchanged and no matrix bound u-PA was detectable by radiometric measurements. The overall rate constant for the bimolecular complex formation was 3.13±0.26 X 106 s-' M-'. As shown in Fig. 4 the amount of complex formed was proportional to the amount of u-PA added to [35S]methionine-labeled matrices. Matrices produced by 5 X I04 BSMCs inhibited 1-1.5 U u-PA. With the dose-dependent increase in complex formation the bands at 41 and 45 kD also increased in intensity.
Characterization of the matrix associated PA inhibitor. The specificity of the inhibitor for u-PA and t-PA was investigated by competitive inhibition studies. When 1251-u-PA was added to matrices with an equal amount of unlabeled u-PA or t-PA a 50% reduction of complexes containing 1251 u-PA was achieved (Fig. 5 B) . While thrombin used did not inactivate the matrix bound inhibitor during the 30-min incubation although higher thrombin concentrations (10 U/well) caused a decrease in 1251I u-PA complexes formed. Furthermore, I251-thrombin (0.1-10 U) did not complex with any matrix component in the presence or absence of heparin, nor was the amidolytic activity of thrombin inhibited upon incubation with the matrix (data not shown). In addition to its specific affinity for u-PA and t-PA, the matrix-associated inhibitor was also stable under acidic conditions. All inhibitory activity was released from the matrix during a 1-h treatment at pH 2.7 (Table I ) and was detectable in supernatants from acid-treated matrices.
SDS-PAGE analysis of biosynthetically labeled acid extracted proteins showed an intense band at 45 kD and a second 56-kD band. In addition two bands of 45 and 56 kD were greatly diminished when the residual matrix proteins were solubilized and analyzed by SDS-PAGE and autoradiography (data not shown). As shown in Fig. 6 A (lanes 1-3) the lower 45-kD band was specifically recognized by the PAI-1 antiserum (lane 2), but not by preimmune rabbit Ig (lane 3). In addition the immobilized PA inhibitor antibodies removed all functional u-PA inhibitory activity from the matrix acid supernatant (Fig. 6 B) so that the presence ofa second acid stable u-PA inhibitor species can be excluded. Thrombin also removed all inhibitory activity from the matrix. When crude supernatants from thrombin-treated matrices where analyzed by SDS-PAGE, they contained a 200-kD band and a 41-kD band (Fig. 6 A, lane 4) . The lower molecular weight species specifically reacted with the PAI-1 antiserum. Similarly when acid extracted 45-kD inhibitor was incubated with thrombin (10 U), a 41 -kD proteolytic fragment was generated.
Intact and modified PAI-1. To compare the functional properties of the intact acid extracted 45-kD PAI-l and the cleaved 41 zymography. As shown in Fig. 7 A (lanes 2 and 3) , the acid extracted PAI-I formed high molecular weight complexes with both u-PA and t-PA and was also functionally active when subjected to reverse zymography ( Fig. 7 B, lane 1) . On the other hand PAI-l released from the matrix by thrombin neither formed high molecular weight complexes (Fig. 7 A, lanes 5 and 6) nor prevented the lysis of the casein in the underlying indicator gel (Fig. 7 B, lane 2) . u-PA and t-PA also cleaved the 56-kD protein but since this protein was neither recognized by the PA inhibitor antiserum nor showed activity on the zymograms, it was not further characterized. It is interesting that incubation of matrices or matrix acid extracts with u-PA and t-PA also resulted in the generation of the two forms of PA inhibitor. The upper band comigrated with PA inhibitor obtained from acid extracts, whereas the lower band showed the same mobility as the thrombin-treated PA inhibitor. Both forms specifically reacted with the PA inhibitor antiserum (Fig. 8, lane 4) . To (Fig. 8,  lane 3) . u-PA must therefore have cleaved the inhibitor during the generation of the covalent u-PA-inhibitor bond.
To further characterize the interaction of PAI-1 with the matrix the effects 0.05% Tween, high salt (2 M NaCl), heparin (100 U/well) or EDTA (25 mM) on the release of matrix bound PA inhibitor were tested (Table I) (Fig. 9 A), zymography (Fig. 9 B) and by immunoprecipitation (Fig. 9  C) . Whereas acid extracts from matrices exposed to BSMCs contained a 45-kD band with functional and antigenic properties of PAI-1, such a protein was lacking in acid extracts from matrices exposed to Bowes melanoma cells. A higher molecular weight protein (Fig. 9 A) as well as other matrix proteins (data not shown) were not significantly affected.
Discussion
We have shown that BSMCs synthesize a functionally active PAI of both u-PA and t-PA that is incorporated into the extracellular matrix. When cells were removed under conditions that did not involve cell lysis (with EDTA or collagenase, data not shown) instead of the routinely used 0.5% Triton X-100, 25 mM NH40H treatment, similar results were obtained. Therefore PAI was not adsorbed onto the matrix after cell lysis. The interaction of PAs with the matrix resulted in rapid and complete enzyme inhibition and the appearance of bimolecular PA-PAI complexes in the supernatant (Fig. 1) . Complexes with identical electrophoretic mobility were also observed when t-PA and u-PA were incubated with matrices from human and bovine endothelial cells and human foreskin or lung fibroblasts thereby demonstrating the ubiquitous nature of this matrix constituent (data not shown). The specific reactivity of the matrix associated PAI for t-PA and u-PA, the (Fig. 6) . Furthermore no functional PAI was detectable in acid extracts from BSMC matrices after immunodepletion with the anti-PAI-I antiserum suggesting the absence of a PAI-2 from BSMC extracellular matrix. PAI-I, the major form of circulating PA inhibitor (40) has previously been implicated in the intravascular control of t-PA activity during fibrinolysis (42) . The molecular weight ofthe matrix associated PAI-I was 45 kD, whereas other published reports range from 47.5 to 54 kD. The reason for this difference remains to be determined. The presence of PAI-I in the extracellular matrix of cells in the vessel wall extends the biological role of PAI-I to the control of PA-mediated events in the extravascular space.
The complex formed between u-PA and the matrix-associated PAI-I was resistant to treatment with SDS and fl-mercaptoethanol. The PAI-I-PA complex demonstrated unusual stability on SDS-PAGE since dissociation did not occur during electrophoresis in the Laemmli gel system but required prolonged incubation in 1 M Tris at pH 1 1. Therefore, the mechanism involved in complex formation of serine proteinase inhibitors with their corresponding proteinases (43) most likely also applies to the complex formed between PAI and u-PA or Extracellular Matrix-associated Plasminogen Activator Inhibitor 1087 A t-PA. The formation of the enzyme inhibitor complex was accompanied by the loss of a 4-5-kD polypeptide so that PAI-1 recovered from the u-PA-PAI-1 complex consisted entirely of the 41-kD modified PAI-l species and not the 45-kD intact PAI-l (Fig. 8) . In addition to the active 45-kD PAM-i species that rapidly complexed with u-PA, substantial amounts of an uncomplexed 45-kD PAI-1 were detectable on SDS-PAGE (Fig. 7) . The reason for the presence of this inactive molecular species remains to be determined. Nevertheless, the inactive 45-kD species remained a good substrate for u-PA since it was cleaved by u-PA in a dose dependent fashion into the 41-kD PAI-I (Fig. 4) (44) . In addition to u-PA and t-PA high concentrations (10 U) of thrombin (Fig. 6 ) or plasmin (data not shown) also cleaved PAI-I into the 4 l-kD functionally inactive species without the formation of SDS stable complexes.
Dissociation of PAI-I from the matrix occurred either during acid treatment that released the intact 45-kD species or by the loss of the 4-5-kD polypeptide during the incubation with u-PA, t-PA, or thrombin. Since cleavage ofPAI-I was not required for its release from the matrix, the disruption of the matrix-PAI-1 bond appears to be mediated through a conformational change in the inhibitor. Furthermore the association of PAI-1 with the matrix could not be disrupted by incubation with 2 M NaCl, EDTA or heparin (Table I) suggesting that the binding was not simply ionic or divalent cation dependent. After its dissociation from the matrix the 45-kD PAI-I quickly lost up to 90% of its activity upon storage at 4°C or freezethawing (data not shown). Therefore the association with the extracellular matrix appears to stabilize the functional activity of PAI-1.
Plasminogen activators have been implicated in the invasive behavior of certain tumor cells. Quigley first demonstrated that PMA-treated Rous sarcoma virus transformed chick embryo fibroblasts when cultured on extracellular matrices undergo a PA-mediated morphological change in the complete absence of plasminogen (45, 46) . Addition of low molecular weight inhibitors of PAs as well as a specific monoclonal antibody that blocked functional PA activity prevented cluster formation of Rous sarcoma virus transformed chick embryo fibroblasts. These experiments strongly suggest that PA has a direct effect on cell matrix interactions. The increased secretion of PAs as a result of cellular transformation facilitates matrix destruction by some tumor cells during their migration through the vessel wall (47) and the establishment of metastasis (48). Ossowski and Reich (49) first showed that antibodies to u-PA considerably diminished the generation of lung metastasis by HEp2 human carcinoma cells seeded onto the chick chorioallantoic membrane, suggesting that u-PA was involved at a crucial step during the formation of metastasis. Furthermore a rat smooth muscle cell extracellular matrix was used to demonstrate inhibition of invasion and cell proliferation by protease nexin of the u-PA producing fibrosarcoma cell line, HT 1080 (50) . Since protease nexin blocks both u-PA and plasmin activity, the exact mechanism of tumor cell invasion in this system remains unknown.
The PA-mediated degradation of chick embryo fibroblast extracellular matrices was characterized by an initial lag period (51) , suggesting that matrix-associated PA inhibitor initially neutralized tumor cell PA. In the present study, matrix acid extracts contained no PAI-1 after exposure of matrices to t-PA producing Bowes melanoma cells (Fig. 9 ). In addition a strain of HT 1080 cells that elaborates copious amounts of u-PA also caused a loss of acid extracted matrix associated PAI-l (data not shown). On the other hand BSMCs, fibroblasts, and an other human melanoma cell line, C32, did not affect matrixassociated PAI-1. The apparent specificity of this effect by certain PA-secreting tumor cells suggests that PAI-l might be removed from the matrix by complex formation with PAs. Alternatively, PAI-1 could be released from the matrix or cross-linked to the matrix by other tumor-associated enzymes. Since the role of PA in matrix remodeling and degradation has clearly been established, the presence of a matrix-associated PA inhibitor may provide an important regulatory component for a number of physiological and pathological processes.
